Robert Popovian
Host at Healthcare Facility Matters
Chief Science Policy Officer at Global Healthy Living Foundation
Pharmacist | Economist | Advocate for Patients, Healthcare Professionals and Employers | Truth Teller! Apple/Spotify Podcast: Healthcare Matters
Articles
-
2 weeks ago |
bizjournals.com | William Smith |Robert Popovian
The Trump administration's “Most Favored Nation” drug pricing hopes to secure prices even lower than Biden's IRA price-control program. The reality of pharmacy benefit managers means that out-of-pocket costs for seniors could go up, not down.
-
Dec 3, 2024 |
jheor.org | Anne Sydor |Esteban Rivera |Robert Popovian
INTRODUCTION As with any complex U.S. federal legislation, the Inflation Reduction Act (IRA), signed into law on August 16, 2022, includes provisions with positive and negative consequences for diverse stakeholders.1 Specific clauses affect health insurance premiums, patients’ out-of-pocket costs, and wholesale medication prices that will impact patients, biopharmaceutical companies, the insurance industry, and policymakers differently, depending on their perspectives and roles within the...
-
Dec 3, 2024 |
INTRODUCTION As with any complex U.S. federal legislation, the Inflation Reduction Act (IRA), signed into law on August 16, 2022, includes provisions with positive and negative consequences for diverse stakeholders.1 Specific clauses affect health insurance premiums, patients’ out-of-pocket costs, and wholesale medication prices that will impact patients, biopharmaceutical companies, the insurance industry, and policymakers differently, depending on their perspectives and roles within the...
-
Sep 9, 2024 |
detroitnews.com | William Smith |Robert Popovian
William Smith and Robert Popovian | The Detroit NewsThe federal 340B Drug Pricing Program was designed to encourage hospitals and clinics to provide low-income patients with more charity care. Today, the program costs taxpayers billions of dollars. Still, there is far more evidence that hospitals are using the money to subsidize unrelated operations than helping those in need. There is an aphorism that says if you are going to say something deceptive, go big.
-
Sep 5, 2024 |
baltimoresun.com | Robert Popovian
Maryland policymakers have touted the Prescription Drug Affordability Board (PDAB) as their solution to high drug prices. Instead of tackling the root causes, these price-setting boards could exacerbate the dominance of pharmacy benefit manager (PBM) owned pharmacies at the expense of community pharmacies. PBMs are supposed to help lower patient costs but often enrich themselves at the expense of patients and community pharmacies.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 4K
- DMs Open
- No
RT @CreakyJoints: A recent peer-reviewed paper co-authored by our Chief Science Policy Officer, Dr. @PopovianPharmD, explores how the Infla…
Another ridiculous excuse by @united in @flyLAXairport, major international airport “limited gate availability” maybe @MayorOfLA should pay attention and ask some tough questions as we go into @WorldCupUS2026 and @Olympics https://t.co/ob0mDOgGBc
HB 2385 is a gift to for-profit PBMs and contract pharmacies who make significantly more dispensing fees from 340B drugs, unlike dispensing meds for Medicaid in OR. Glad to see OR legislators are contributing to corporate welfare they so much despise. @GovTinaKotek #VetoHB2385